FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma

The US FDA approved daraxonrasib, a first-in-class daily oral RAS inhibitor, for metastatic pancreatic adenocarcinoma patients who have had prior systemic therapy or are ineligible for multiagent systemic treatment, offering a chemotherapy-free targeted therapy that doubles survival.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it.